These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 19503098)
1. Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas. Thornber K; Colomba A; Ceccato L; Delsol G; Payrastre B; Gaits-Iacovoni F Oncogene; 2009 Jul; 28(29):2690-6. PubMed ID: 19503098 [TBL] [Abstract][Full Text] [Related]
2. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro. Hsu FY; Zhao Y; Anderson WF; Johnston PB Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934 [TBL] [Abstract][Full Text] [Related]
3. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649 [TBL] [Abstract][Full Text] [Related]
4. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Hsu FY; Johnston PB; Burke KA; Zhao Y Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741 [TBL] [Abstract][Full Text] [Related]
5. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Colomba A; Courilleau D; Ramel D; Billadeau DD; Espinos E; Delsol G; Payrastre B; Gaits-Iacovoni F Oncogene; 2008 Apr; 27(19):2728-36. PubMed ID: 17998938 [TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887 [TBL] [Abstract][Full Text] [Related]
7. Apoptosis of W256 carcinosarcoma cells of the monocytoid origin induced by NDGA involves lipid peroxidation and depletion of GSH: role of 12-lipoxygenase in regulating tumor cell survival. Tang DG; Honn KV J Cell Physiol; 1997 Aug; 172(2):155-70. PubMed ID: 9258337 [TBL] [Abstract][Full Text] [Related]
8. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential. Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017 [TBL] [Abstract][Full Text] [Related]
9. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Lu L; Ghose AK; Quail MR; Albom MS; Durkin JT; Holskin BP; Angeles TS; Meyer SL; Ruggeri BA; Cheng M Biochemistry; 2009 Apr; 48(16):3600-9. PubMed ID: 19249873 [TBL] [Abstract][Full Text] [Related]
10. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Turner SD; Tooze R; Maclennan K; Alexander DR Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401 [TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833 [TBL] [Abstract][Full Text] [Related]
12. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112 [TBL] [Abstract][Full Text] [Related]
13. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma. Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012 [TBL] [Abstract][Full Text] [Related]
14. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation. Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210 [TBL] [Abstract][Full Text] [Related]
15. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma. Armanious H; Gelebart P; Anand M; Lai R Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582 [TBL] [Abstract][Full Text] [Related]
16. Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK. Uchihara Y; Ueda F; Tago K; Nakazawa Y; Ohe T; Mashino T; Yokota S; Kasahara T; Tamura H; Funakoshi-Tago M PLoS One; 2017; 12(8):e0183003. PubMed ID: 28806414 [TBL] [Abstract][Full Text] [Related]
17. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821 [TBL] [Abstract][Full Text] [Related]